Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.[ Read More ]
The intrinsic value of one LUCD stock under the base case scenario is HIDDEN Compared to the current market price of 0.987 USD, Lucid Diagnostics Inc. is HIDDEN
Current Assets | 22.1 M |
Cash & Short-Term Investments | 18.9 M |
Receivables | 45 K |
Other Current Assets | 3.13 M |
Non-Current Assets | 5.2 M |
Long-Term Investments | 0 |
PP&E | 2.64 M |
Other Non-Current Assets | 2.56 M |
Current Liabilities | 29.4 M |
Accounts Payable | 1.15 M |
Short-Term Debt | 15.1 M |
Other Current Liabilities | 13.2 M |
Non-Current Liabilities | 199 K |
Long-Term Debt | 199 K |
Other Non-Current Liabilities | 0 |
Revenue | 2.43 M |
Cost Of Revenue | 8.48 M |
Gross Profit | -6.05 M |
Operating Expenses | 42.4 M |
Operating Income | -48.5 M |
Other Expenses | 4.18 M |
Net Income | -52.7 M |
Net Income | -52.7 M |
Depreciation & Amortization | 2.5 M |
Capital Expenditures | -221 K |
Stock-Based Compensation | 6.82 M |
Change in Working Capital | 5.68 M |
Others | 5.78 B |
Free Cash Flow | -33 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 year ago
Sep 25, 2023
|
Sell 286 USD
|
Lapidus Stanley
Director |
- 200
|
1.43 USD |
1 year ago
Sep 26, 2023
|
Sell 14.7 K USD
|
Lapidus Stanley
Director |
- 10000
|
1.474 USD |
1 year ago
Sep 26, 2023
|
Sell 14.3 K USD
|
Lapidus Stanley
Director |
- 10000
|
1.43 USD |
1 year ago
Sep 26, 2023
|
Sell 14.1 K USD
|
Lapidus Stanley
Director |
- 9747
|
1.45 USD |
1 year ago
Sep 20, 2023
|
Sell 4.94 K USD
|
Lapidus Stanley
Director |
- 3405
|
1.45 USD |
1 year ago
Sep 20, 2023
|
Sell 593 USD
|
Lapidus Stanley
Director |
- 412
|
1.44 USD |
1 year ago
Sep 21, 2023
|
Sell 144 USD
|
Lapidus Stanley
Director |
- 100
|
1.44 USD |
1 year ago
Sep 20, 2023
|
Sell 4.94 K USD
|
Lapidus Stanley
Director |
- 3405
|
1.45 USD |
1 year ago
Sep 20, 2023
|
Sell 593 USD
|
Lapidus Stanley
Director |
- 412
|
1.44 USD |
1 year ago
Sep 21, 2023
|
Sell 144 USD
|
Lapidus Stanley
Director |
- 100
|
1.44 USD |
2 years ago
Sep 20, 2022
|
Sell 29 K USD
|
Lapidus Stanley
Director |
- 17000
|
1.7067 USD |
2 years ago
Sep 20, 2022
|
Sell 28.7 K USD
|
Lapidus Stanley
Director |
- 16864
|
1.7 USD |
3 years ago
Oct 18, 2021
|
Bought 8 M USD
|
PAVmed Inc.
10 percent owner |
+ 571428
|
14 USD |